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Abstract. Peripheral nerve injury is followed by Waller- 
ian degeneration which is characterized by cellular and 
molecular events that turn the degenerating nerve into 
a tissue that supports nerve regeneration. One of these 
is the removal, by phagocytosis, of myelin that contains 
molecules which inhibit regeneration. We have recently 
documented that the scavenger macrophage and 
Schwann cells express the galactose-specific lectin 
MAC-2 which is significant to myelin phagocytosis. In 
the present study we provide evidence for a mechanism 
leading to the augmented expression of cell surface 
MAC-2. Nerve lesion causes nonneuronal ceils, pri- 
marily fibroblasts, to produce the cytokine granulocyte 
macrophage-colony stimulating factor (GM-CSF). In 
turn, GM-CSF induces Schwann cells and macrophages 
to up-regulate surface expression of MAC-2. The pro- 
posed mechanism is based on the following novel ob- 
servations. GM-CSF mRNA was detected by PCR in in 
vitro and in vivo degenerating nerves, but not in intact 
nerves. The GM-CSF molecule was detected by ELISA 
in medium conditioned by in vitro and in vivo degener- 
ating peripheral nerves as of the 4th h after injury. GM- 
CSF activity was demonstrated by two independent 
bioassays, and repressed by activity blocking antibod- 
ies. Significant levels of GM-CSF were produced by 
nerve derived fibroblasts, but neither by Schwann cells 
nor by nerve derived macrophages. Mouse rGM-CSF 
enhanced MAC-2 production in nerve explants, and 
up-regulated cell surface expression of MAC-2 by 
Schwann cells and macrophages. Interleukin-l13 up-reg- 
ulated GM-CSF production thus suggesting that injury 
induced GM-CSF production may be mediated by in- 
terleukin-l[3. Our findings highlight the fact that fibro- 
blasts, by producing GM-CSF and thereby affecting 
macrophage and Schwann function, play a significant 
role in the cascade of molecular events and cellular in- 
teractions of Wallerian degeneration. 
p 
ERIPHERAL nerve injury is followed by Wallerian de- 
generation of the nerve segment situated distal to 
the lesion  site  (26). Molecular and cellular  events 
that take place during the course  of Wallerian degenera- 
tion turn the degenerating nerve into an environment that 
supports the regeneration of peripheral and central adult 
neurons (4, 7). Cellular events that characterize Wallerian 
degeneration are the breakdown of axons,  the prolifera- 
tion of Schwann  cells,  the  recruitment of macrophages 
from the circulation, and the removal of myelin by phago- 
cytosis by macrophages and Schwann cells. It has been re- 
cently demonstrated that myelin-associated glycoprotein 
(MAG)  1, a component of central and peripheral myelin, is 
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a potent inhibitor of axonal growth (20, 22). A rapid and 
efficient mechanism for the removal of myelin is required, 
therefore, for successful regeneration. 
We have recently documented (28) that Schwann cells 
and blood born macrophages express  the galactose spe- 
cific lectin MAC-2 in their cytoplasm and on their surfaces 
during the course of WaUerian degeneration of mice pe- 
ripheral nerves.  We have further provided evidence sug- 
gesting that cell surface MAC-2 mediates myelin phagocy- 
tosis. Furthermore, MAC-2 is considered a "macrophage 
activation marker" due to the fact that its expression is up- 
regulated in activated phagocytic macrophages (10). There- 
fore, MAC-2 is significant to myelin removal and, in turn, 
to nerve regeneration for either one or two reasons.  One, 
MAC-2 may be directly involved in mediating myelin phago- 
cytosis. Second, MAC-2 marks activated macrophages re- 
gardless of the type(s) of phagocytic mechanism(s) they use. 
The vast majority of Schwann cells and activated mac- 
rophages that take part in Wallerian degeneration express 
MAC-2 on their surfaces  (28). In contrast, Schwann cells 
that reside in intact nerves do not express  MAC-2 at all 
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the pool of blood monocytes of which only 60-70%  ex- 
press cell surface MAC-2 at very low levels (23, 24). The 
percentage of macrophages that display cell surface MAC-2 
and levels of expression  of MAC-2 by individual ceils are 
subject  to modulation by changing environmental condi- 
tions (12, 23, 24). Furthermore, granulocyte macrophage 
colony stimulating factor (GM-CSF) activates macrophages 
and concomitantly  up-regulates MAC-2 expression (10). It 
is  most probable,  therefore, that macrophages that be- 
come activated while  being recruited into degenerating 
nerves are also induced to up-regulate surface expression 
of MAC-2. In the present study, we sought after a mecha- 
nism which, in injured nerves, up-regulates cell surface ex- 
pression of MAC-2 in macrophages and Schwann cells. 
We have studied GM-CSF expression  in intact and in- 
jured peripheral nerves of C57/BL/6NHSD  mice that dis- 
play the normal rapid progression of Wallerian degenera- 
tion. We have previously documented some of the events 
and reviewed others (28). The nonneuronal cells residing 
in intact nerves are primarily Schwann, fibroblasts, and en- 
dothelial. After nerve transection, segments situated distal 
to lesion sites undergo Wallerian degeneration. Macrophages 
start being recruited into the degenerating nerve during 
the third day of Wallerian degeneration, where they be- 
come numerous during the fourth day. Axonal degeneration, 
myelin destruction, and myelin removal by phagocytosis 
are completed 5-7 d after axotomy. The rapid progression 
of Wallerian degeneration is correlated with a concurrent 
rapid rise of MAC-2 expression by Schwann ceils and mac- 
rophages. 
In the  present  study we  demonstrate that peripheral 
nerve injury induces the production of GM-CSF, primarily 
by fibroblasts,  within 4-5  h.  GM-CSF, in turn, induces 
Schwann cells and macrophages to up-regulate cell surface 
expression of MAC-2. The up-regulation of GM-CSF pro- 
duction is mediated by interleukin-1  (IL-1).  Our findings 
stress the significant role that fibroblasts  play in the cas- 
cade of molecular events and cellular interactions of Wal- 
lerian degeneration. 
Materials and Methods 
Animals and Surgical Procedures 
The experimental protocol was approved by the authority for research 
and  development  of  the  Hebrew  University  of  Jerusalem.  C57/BL/ 
6NHSD mice (Harlan Sprague Dawley Inc., Jerusalem, Israel), 6--8-too- 
old were used. Surgical procedures were performed under anesthesia. Sci- 
atic nerves were transected after leaving the pelvis. Nerve explants were 
obtained by placing intact nerve segments in culture kept in a humidified 
incubator, saturated by 5% CO2 at 37°C. Freeze damaged nerves were ob- 
tained by three cycles of freeze/thaw of nerve segments that were placed 
back into the donor animals. 
Culture Medium 
Medium used to culture bone marrow derived cells was the Modified Ea- 
gle Minimum Essential Medium alpha, supplemented by 10% FCS, and 
1% of the following standard solutions (Beit-Haemek, Beit-Haemek, Is- 
rael): nonessential amino acids, vitamins, sodium pyruvate, and penicillin] 
streptomycin, and 10 ixg/ml transferrin (Sigma Chemical Co., St. Louis, 
MO). Medium used to culture nerve explants, Schwann cells, and fibro- 
blasts was the DME supplemented by 10% FCS and 1% penicillin]strep- 
tomycin solution (Beit-Haemek). 
Cell Dissociation and Culture 
Nonneuronal single cell type cultures were obtained by enzymatic dissoci- 
ation and differential adhesion plating from either intact, or in vitro or in 
vivo degenerating, or freeze-damaged nerves, as previously described (28, 
30). The different cell types were distinguished from each other by their 
distinct morphology and immunocytochemistry (F4/80 for macrophages, 
S-100 for Schwann, and MAC-2 for both) (28).  Single cell cultures used 
were at least 95% pure. 
Bone Marrow-derived  Macrophage  Precursor Cells 
(1, 36). Bone marrow cells from 1-2-mo-old BALB/c mice were incubated 
in 10% medium conditioned by the L929 cell line that produces the mac- 
rophage colony stimulating factor (M-CSF). Surviving nonadherent cells, 
the macrophage precursor ceils, were collected and further used for test- 
ing GM-CSF activity. 
Conditioned Medium 
Intact, in vitro degenerating, and in vivo degenerating nerves were cut and 
washed for 1 h  in DME, and then incubated in DME supplemented by 
10% FCS (0.25-0.5  ml/nerve) in a humidified incubator saturated by 5% 
C02 at 37°C. Each sample of CM was produced by two to four nerves. 
Macrophage, Schwann and fibroblast cell cultures were also used to con- 
dition medium. Wet weights of tissues and DNA content of cell cultures 
were determined. Then, the proportion of volumes conditioned by either 
1 mg of wet weight tissue, or by the equivalent of I  ng of DNA of cells 
were calculated. DNA levels were determined by fluorescence emission of 
the Hoechst 33258 stain at a wave length of 458 nm (18). 
GM-CSF mRNA Detection by In Vitro Amplification 
of GM-CSF cDNA 
Nerve tissues (50 mg) were homogenized in 1 ml lysis/binding  buffer (Tris- 
HC1, pH 8.0, 0.5 M LiCI, 10 mM EDTA, 1% SDS, 1 mM dithiothreitol), 
centrifuged (30 s at 13,000 rpm), and supernates transferred to tubes con- 
taining 1 mg oligo dT linked magnetic beads (Dynal AS, Oslo, Norway). 
Annealing washing and elution of poly A  RNA linked beads was per- 
formed by using the Dynal MPC-E magnet according the manufacturers 
instructions. 
eDNA synthesis of polyA RNA was performed using the "first strand 
eDNA synthesis kit" (Amersham Buckinghamshire, UK) with oligo dT as 
primer. The GM-CSF eDNA was amplified using GM-CSF sense (AGC- 
ATGTAGAGGCCAATCAAAGAAGC) and anti-sense (TGCATTCAA- 
AGGGGATATCAGTCAGA) oligonucleotide primers synthesized (Gen- 
eral  Biotechnology,  Rehovot,  Israel)  following  published  sequences 
(GenBank/EMBL/DDBJ). For in vitro eDNA amplification, 12.5 pmole 
primers, 64  ixM dNTP's and 1.25 U  Taq polymerase (Boeringer-Mann- 
heim, Mannheim, Germany) were added to the incubation buffer, and the 
entire mixture overlaid by mineral oil and heated to 96°C for 4 rain in a 
MJ Research Programmable Thermal Controller. The in vitro amplifica- 
tion was carried out for 40 cycles at the following temperature profile: 
96°C for 4 rain (denaturation), 55°C for 1 rain (annealing), 72°C for 1 rain 
(primer extension). Negative controls consisted of the identical poly A 
RNA preparations that were subjected to the same procedures as above 
but with the omission of reverse transcriptase. Poly A RNA preparations 
purified from the GM-CSF producing cell line BMS2 were used as posi- 
tive controls. The amplification products were visualized by ethidium bro- 
mide after separation on a 3% agarose gel. DNA molecular weight mark- 
ers (pBR328/Bgl I and pBR328/Hinf I) were used. The reaction product 
was sequenced by an Applied Biosystems sequencer to verify that it was 
indeed the GM-CSF eDNA. 
Identification and Quantitation of GM-CSF by ELISA 
To identify and quantify GM-CSF in CM we used the two site sandwich 
ELISA  (Pharmingen, San  Diego,  CA)  according to  manufacturers  in- 
structions. Concentrations of GM-CSF were determined from standard 
curves that were constructed for each experiment using recombinant GM- 
CSF (rGM-CSF) at a concentration range from 0-1,600 pg/ml. 
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by the Granulocyte-Macrophage (GM) 
Colony Formation Assay 
GM-CSF activity can be detected (21) based on its unique ability to form 
mixed granulocyte-macrophage colonies from single precursor cells. Bone 
marrow cells (3 x  10S/ml) in soft agar (0.25%) were overlaid on nerve ex- 
plants undergoing in vitro degeneration or on monolayers of fibroblasts or 
Schwann cells. After 7-10 d, cells were fixed (PAF), agar dried, colonies 
stained by hematoxylin, and cell types identified by light microscopy. 
Macrophage Precursor Cell Differentiation Assay 
We have developed an assay system to detect GM-CSF bioactivity. The 
assay is based on two facts. One, in the absence of any other cytokine, 
bone marrow derived macrophage precursor (MP) cells depend on GM- 
CSF  for their survival and  differentiation into mature monocytesJmac- 
rophages. Second, the ability of a mAb raised against rGM-CSF to inhibit 
GM-CSF bioactivity, rGM-CSF rescued and induced the differentiation of 
MP cells into mature macrophages in a dose-dependent manner (Fig. 1). 
Hence, surviving cells expressed molecules that characterize mature mac- 
rophages: MAC-I, MAC-2, the Fc receptor, and the F4/80 antigen (2, 13, 
24, 25) (see Fig. i for MAC-2 and the F4/80 antigen). The activity of rGM- 
CSF, judged by the number of surviving  cells and levels of MAC-2 expres- 
sion (see results below and Fig. 3), was inhibited 50% to 60% by a mAb 
raised against rGM-CSF. We have chosen to follow GM-CSF activity by 
monitoring levels of cell surface associated MAC-2 by ELISA for two rea- 
sons. One, the relationship between GM-CSF and surface expression of 
MAC-2 is the focus of our interest. Second, one can easily and reliably de- 
termine MAC-2 on adherent cells by ELISA (see below). 
Bone marrow derived MP cells were seeded in 96 well dishes at a den- 
sity of 80 x  103/well. To determine a dose response curve for rGM-CSF, 
various dilutions of rGM-CSF (Genzyme, specific activity of 106 U/mg) 
were added to test wells in which the final incubation volume reached 0.2 
ml. Each dilution was repeated five times. Surviving, adherent cells were 
studied by ELISA or immunofluorescence  light microscopy after 4 d. 
To  test whether nonneuronal cells  that  reside  in  intact  or  lesioned 
nerves conditioned medium with GM-CSF activity, various dilutions of 
CM were added to test wells. For each sample of CM, the concentrations 
used were the proportions of volume conditioned by 180, 60, 20, 6.6, 2.2, 
and 0.7 I~g of wet weight tissue, in a final volume of 0.2 ml. These are re- 
ferred to in the text as dilutions 1 through 7. Concentrations used to test 
CM produced by either fibroblasts, Schwann cells or macrophages were 
the proportions of volume conditioned by the equivalents of 180, 60, 20, 
6.6, 2.2, 0.7, and 0.23 ng DNA of cells, in a final volume of 0.2 ml. These 
are referred to in the text as dilutions 1 through 7. The design of experi- 
ments was such that each sample of CM was tested in several dilutions to 
obtain a dose response curve. Each dilution step was tested in quadrupli- 
cates. In parallel,  a  dose-response curve of rGM-CSF was determined. 
Levels of GM-CSF activity in CM were calculated from the ratio of MAC-2 
expression induced by dilution 3 of CM over that induced by 7.4 pg/ml of 
rGM-CSF. 
To determine whether the ability of CM to rescue and lead to the dif- 
ferentiation of MP cells into mature monocytes/macrophages is due to 
GM-CSF activity, we tested the ability of a mAb raised against rGM-CSF 
(Genzyme, Boston, MA) to inhibit CM activity. CM (0.1 ml of dilution 3) 
and rGM-CSF (0.1 ml of 7.4 pg/rnl) were incubated for 1 h at 37°C with 2 
Ixg of the mAb. The mixture was then added to the wells containing MP 
cells (in 0.1 ml of medium). Percent inhibition was calculated from the ra- 
tio of MAC-2 expression induced by the tested sample in the presence of 
the mAb over that induced by the same sample in the absence of the mAb. 
ELISA Determination of Cell Surface-associated 
MA  C-2 Levels 
We followed the protocol described in reference 1 with some modifica- 
tions. Adherent cells were washed three times at 37°C with Ca/Mg/PBS, 
fixed  at  37°C for  30  min with  4%  parafomaldehyde  (in  Ca/Mg/PBS), 
washed 3×  in  PBS,  blocked  over night at 4°C with 3%  BSA in  PBS, 
washed 3x in PBS, incubated up to 2 h  at room temperature with a 1:10 
dilution (in 1% BSA in PBS) of the mAb M3/38, washed 4x in PBS, incu- 
bated for 1 h  in a  1:5,000  dilution (in 1% BSA in 50 mM Tris, 100 mM 
NaCI, pH 8) of alkaline phosphatase conjugated goat anti-rat IgG (Jack- 
son ImmunoResearch, Avondale, PA), washed 4x in PBS, incubated for 2 
h  at room temperature  with substrate solution (1  mg/ml p-nitrophenyl 
phosphate sodium in 10% diethanolamine, pH 9.8; Sigma Chemical Co., 
St.  Louis, MO).  The  reaction  product  was  read  in  a  Dynatec ELISA 
reader at 405 nm wavelength. 
ELISA Determination of  MAC-2 Levels in Tissues 
Nerves were homogenized for 2 min in 50 mM sodium carbonate buffer, 
pH 10.0, in a volume of 0.3 ml/nerve, and further incubated for 1 h at 37°C. 
0.1 ml/nerve of 0.5 M  sodium carbonate, pH 9.6,  was added to samples 
that were then vortexed and centrifuged for 10 min at 15,000 g. Protein 
contents of supernates were determined (protein assay reagent, BioRad 
Laboratories,  Cambridge, MA),  protein  concentration  adjusted to  12.5 
ixg/ml with sodium carbonate buffer, pH 9.6, and 50 Ixl of serial dilutions 
were  used to  coat 96-well plates  (Maxisorb Immuno Plates 96F; Nunc, 
Roskilde, Denmark) over night at 4°C. Wells were washed 2× with TBS, 
blocked for 2  h  at 37°C with 2% gelatin (Sigma Chemical Co.) in TBS, 
washed 2× with 0.1% Tween 20 in TBS (TBST), incubated over night at 
4°C with mAb M3/38 (diluted 1:50 in 1% BSA in PBS), washed 2x with 
TBST, incubated for 1 h in a 1:5,000 dilution (in 1% BSA in 50 mM Tris, 
100 mM NaCI, pH 8.0) of alkaline phosphatase conjugated goat anti-rat 
IgG  (Jackson  ImmunoResearch), washed 4x  in  PBS, incubated for  as 
long as required  at room temperature with substrate solution (1 mg/ml 
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Figure  1.  rGM-CSF  induces 
MP cells to differentiate into 
macrophages  that  express 
MAC-2  and  the  F4/80  anti- 
gen  on  their  surface.  (A) 
rGM-CSF  induces  MP  cells 
to  differentiate  into  macro- 
phages  that  express  MAC-2 
on their surface in a  dose de- 
pendent  manner.  Levels  of 
cell surface MAC-2 were de- 
termined  by  ELISA  on  ad- 
herent  surviving  cells,  and 
are presented in optical den- 
sity units. Each data point is 
the  average  of  five  repeti- 
tions,  error  bars  -+1  SEM. 
rGM-CSF concentrations are 
given in a  logarithmic scale. (B) MP cells were incubated for 4 d  in the presence of 60 pg/ml of rGM-CSF, and then stained immunohis- 
tochemically by a  mAb  raised against the F4/80 antigen. Surviving adherent cells are mature macrophages since they display the F4/80 
antigen which is specific to this cell type. Bar, 50 p~m. 
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Chemical Co.). The reaction product was read in a Dynatec ELISA reader 
at 405 nm wavelength. 
Immunofluorescence  Microscopy 
We have used immunofluorescence microscopy  to visualize  the cell sur- 
face antigens MAC-l, MAC-2, Fc,  and F4/80,  and intracellular MAC-2 
and S-100 as previously described (28). 
Antibodies Used 
Immunocytochemistry.  mAbs raised against MAC-l, F4/80 antigen, and 
Fc receptor (Serotec, Oxford, England), supernates of the hybridoma cell 
line M3/38 that produces anti MAC-2 mAb (American Type Culture Col- 
lection, Rockville,  MD), anti S-100 and FITC-conjugated rabbit anti-rat 
IgG (Bio-Makor, Rehovot, Israel). 
ELISA determination of cell surface MAC-2 and tissue content of MA C- 
2: the anti-MAC-2 mAb, as above. 
Two site sandwich ELISA  determination of GM-CSF content: capture 
and detecting antibodies (Pharmingen, USA), alkaline phosphatase con- 
jugated IgG (Jackson, USA). 
GM-CSF activity blocking: anti GM-CSF mAb (Genzyme, Cambridge, 
MA). 
Results 
GM-CSF Production in Lesioned Peripheral Nerves 
Degenerating peripheral  nerves produced detectable  lev- 
els of GM-CSF as of the fourth hour after nerve injury and 
through  the  entire  2  wk  tested.  Intact  nerves  and  nerve 
segments situated distal to sites of nerve transection were 
incubated in medium for 5 h. Nonneuronal cells that reside 
in these  tissues  conditioned  medium  (CM)  by molecules 
they synthesize and secrete. CM were tested by ELISA to 
determine  whether  and  to  what  extent  is  GM-CSF  pro- 
duced by the nonneuronal cells  that reside  in the Walle- 
rian  degenerating nerves  (Fig. 2).  GM-CSF was detected 
in CM produced by intact nerves during their first 5 h  of 
incubation,  immediately after removal from animals  (the 
first  data  point  in  Fig.  2).  We  further  tested  production 
during each and every one of these first 5 h using three dis- 
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Figure 2. The time course of 
GM-CSF production  by  de- 
generating  nerve  segments. 
Nerve segments situated dis- 
tal to sites  of nerve transec- 
tion were removed from two 
different batches  of mice at 
various  times  after  surgery, 
and allowed to condition me- 
dium for 5  h.  CM were  as- 
sayed,  by two site  sandwich 
ELISA,  for  GM-CSF  con- 
tent. Then, GM-CSF produc- 
tion  was  calculated  (pg/mg 
wet weight of nerve tissue/5 h). 
Each data point is placed on 
the time axis in accordance to the post surgery day  +  5  h. The 
first data point for each batch of mice reflects GM-CSF produc- 
tion by the intact nerve during the first 5 h  of in vitro degenera- 
tion taking place at the time of incubation. All other data points 
reflect  GM-CSF  production  in  Wallerian  degenerating  nerves. 
The  two  batches  of  mice  differ  in  the  magnitude  of their  re- 
sponse. Data points are the average of three distinct experiments. 
Error bars _ 1 SEM. 
Figure 3.  GM-CSF  mRNA  is  ex- 
pressed in in vitro and in vivo de- 
generating nerves. PolyA RNA was 
isolated  from intact,  16  h  in vitro 
degenerating nerves, two and six d 
in  vivo  degenerating  nerves,  and 
from  BMS2  cells.  Poly  A  RNA 
samples  were  used  to  synthesize 
cDNA which was then amplified by 
PCR. Reaction products were sepa- 
rated by agarose gel electrophore- 
sis. (A) The expected 315-bp  PCR 
reaction  product  indicating  the 
presence  of GM-CSF mRNA was 
not detected in intact nerves (1), it 
was detected in 24 h in vitro degen- 
erating nerves (2),  and 2 d in vivo 
degenerating nerves  (3).  The GM- 
CSF mRNA was  also  detected  in 
GM-CSF  producing  BMS2  cells 
(not shown). Negative controls were PCR reactions that included 
polyA RNA  samples  that  had  the  GM-CSF  mRNA  but  not 
cDNA in them, and samples containing the GM-CSF sense and 
antisense  primers but neither the GM-CSF mRNA nor cDNA 
(not shown). (B) The PCR reaction product indicating the pres- 
ence of 13-actin was detected in all preparations. 
tinct samples of CM. GM-CSF was first detected (sensitiv- 
ity of assay 8 pg/ml) in two samples during the fourth, and 
in all samples during the fifth consecutive hour of incuba- 
tion. GM-CSF production continued for the entire 14 d of 
Wallerian  degeneration  tested,  Levels  of production  dif- 
fered between animals of different purchases from vendor. 
GM-CSF mRNA was detected in in vitro and in vivo de- 
generating but not intact nerves.  We tested for the pres- 
ence of the GM-CSF mRNA by in vitro amplification of 
GM-CSF  cDNA obtained  by cDNA synthesis  of polyA 
RNA  isolated  from  intact  and  lesioned  nerves  (Fig.  3). 
GM-CSF mRNA  was  never  detected  in  any one  of five 
distinct  polyA RNA isolations from intact nerves.  It was 
detected in every one of five distinct isolations from 16 h 
in vitro degenerating nerves.  It was detected in three out 
of six distinct  isolations  from 2-6 d  in vivo degenerating 
nerves. We verified that the reaction product is indeed the 
GM-CSF cDNA by sequencing  it,  and by performing in 
vitro amplification of GM-CSF cDNA that was obtained 
by cDNA synthesis of poly A  RNA isolated from the GM- 
CSF producing BMS2 cell line (not shown). It is not clear 
to us why is it that we could not demonstrate the GM-CSF 
mRNA in  each  one of the isolations  from Wallerian  de- 
generating nerves.  One possible explanation could be the 
instability of the GM-CSF mRNA (32, 34, 37), which may 
account also, at least in part, for the variability in GM-CSF 
levels detected  during the course of Wallerian  degenera- 
tion (Fig. 2). 
GM-CSF Activity Production in Lesioned 
Peripheral Nerves 
GM-CSF produced  by in vivo and in  vitro  degenerating 
nerves is biologically active. CM were tested for GM-CSF 
activity using the bone marrow-derived MP cell differenti- 
ation assay. We have used this system to test for GM-CSF 
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tiation of MP cells into mature adherent macrophages that 
express MAC-2, the molecule which is the focus of our in- 
terest  (see Materials  and  Methods  and Fig.  1).  CM of 5 
and 24 h in vitro degenerating nerve explants, and 5-7 d in 
vivo degenerating nerves led to the survival and differenti- 
ation of MP cells into MAC-2 positive macrophages in a 
dose dependent manner (Fig. 4 A). To quantify, we com- 
pared levels of activity produced by a standard amount of 
tissue (dilution 3 of CM) to levels of activity produced by a 
standard concentration of rGM-CSF (7.4 pg/ml) (Fig. 5 A). 
Levels of activity produced were largest for CM of 5-7 d in 
vivo degenerating nerves (59.1%), less for CM of 24 h  in 
vitro degenerating explants (15.3%), and the least for CM 
of 5 h in vitro degenerating explants (2.6%). 
GM-CSF activity blocking mAb repressed GM-CSF ac- 
tivity present in CM. The average levels of inhibition ob- 
tained were 58.5% of the activity of rGM-CSF (7.4 pg/ml), 
and 83.3 and 56.4% of the activities produced by CM (di- 
lution 3) of 24 h in vitro degenerating explants and 5-7 d in 
vivo degenerating nerves, respectively (Fig. 5 B).  In five 
inhibition  experiments  involving  rGM-CSF  (7.4  pg/ml), 
the number of surviving cells were counted: inhibition av- 
eraged 51.6%  +  2.5% (SEM). Cell survival was also tested 
on two different samples of CM (dilution 3) produced by 
5-7  d  in  vivo degenerating  nerves:  repression  averaged 
56.8%. The mAb thus inhibited the activities of rGM-CSF 
and CM to about the same extent with regard to MAC-2 
expression and cell survival. 
We tested the in vitro production  of GM-CSF activity 
using an additional bioassay: the mixed granulocyte-mac- 
rophage (GM) colony formation assay (21).  The unique- 
ness of GM-CSF is in its ability to induce single bone mar- 
row  precursor  cells  to  form mixed  GM  colonies.  Intact 
nerve explants were overlaid by bone marrow cells in soft 
agar. Mixed colonies were detected after 7-10 d of culture 
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Figure 4.  Lesioned peripheral nerves and nerve derived fibro- 
blasts produce CM that like rGM-CSF (Fig. 1) induce MP ceils to 
differentiate into macrophages expressing cell surface MAC-2 in 
a dose-dependent manner. (A) Examples of CM produced by 5-7 d 
in vivo degenerating nerves (Deg), and 5 (Ex-5) and 24 h (Ex-24) 
in vitro degenerating nerve explants.  (B) Examples of CM pro- 
duced by fibroblasts (Fib), Schwann cells (Sch), and macrophages 
(Mac). The values  obtained for Schwann  and macrophages are 
similar,  and  their symbols  overlay.  Levels of MAC-2 are pre- 
sented in optical density units. Each dilution of CM represents a 
volume of medium conditioned  by equal amounts of tissues (A) 
or equal numbers of cells (B),  each dilution  step was tested in 
quadruplicates  and represents a threefold decrease in CM con- 
centration.  Error bars _+ 1 SEM. 
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Figure 5.  The ability of CM of lesioned nerves and of rGM-CSF 
to induce  MP cells to differentiate into macrophages expressing 
MAC-2 is inhibited  by a GM-CSF activity blocking monoclonal 
antibody.  (A) 5 and 24 h  in vitro degenerating nerve explants 
(Ex-5 and Ex-24), and 5-7 d in vivo degenerating nerves (Deg) 
differ in the levels of GM-CSF activity they produce. Levels of 
activity were calculated from the ratio of cell surface MAC-2 ex- 
pression  induced by CM (dilution  3) over that induced  by rGM- 
CSF (7.4 pg/ml). Averages differ significantly (Ex-5 over Ex-24 
P <  0.012, Ex-5  over Deg P  <  0.004, by the two-tailed  Mann 
Whitney U test). (B) A mAb raised against rGM-CSF inhibits the 
activity of CM (dilution 3) produced by 24 h in vitro degenerating 
explants (Ex-24) and by 5-7 d in vivo degenerating nerves (Deg) 
to the same extent as, or more than,  it inhibits  the activity  of 
rGM-CSF (7.4 pg/ml).  Bars represent averages,  error bars  -+1 
SEM, n = number of experiments.  Four nerves were examined in 
each one of the experiments that were done in quadruplicates. 
thus  indicating  the  presence  of GM-CSF  activity in  the 
medium. 
The time course of GM-CSF production by in vitro de- 
generating nerves is phasic. We examined the time course 
of GM-CSF production  during  in  vitro  degeneration  by 
the MP differentiation assay at 24 h  time intervals. Nerve 
explants were incubated in fresh medium for time periods 
alternating between 5 and 19 h for 5 d. CM obtained dur- 
ing the first 5 h of each day were tested. GM-CSF activity 
production was about threefold higher during the second 
day of in vitro degeneration than during the first day. As 
of the  third  day and  through the  fifth day it declined  to 
about the same or lower levels than those produced during 
the first. This phasic in vitro production of GM-CSF was 
verified by determining GM-CSF in CM by ELISA. 
GM-CSF Production by Nerve-derived Fibroblasts, 
Macrophages, and Schwann Cells 
Nerve derived fibroblasts but neither  Schwann  nor mac- 
rophages produce significant levels of GM-CSF. The non- 
neuronal cell population of intact nerves and intact nerve 
explants are primarily Schwann and fibroblasts. Macrophages 
are scarce, but increase in number following injury, conse- 
quent to their recruitment from the circulation (28, 31, 35). 
Fibroblast cell cultures were established either from intact 
nerves or 6 d  in vivo degenerating nerves. Fibroblast cul- 
tures were first obtained 2 d after the beginning of cell dis- 
sociation.  Thereafter, fibroblasts were  allowed  to  condi- 
tion medium for 16 h. Fibroblasts CM were tested by the 
MP cell differentiation assay and found to contain signifi- 
cant levels of GM-CSF activity (Fig. 4 B). In three experi- 
ments  involving  CM  (dilution  1)  of fibroblasts obtained 
from  intact  nerves,  activity  averaged  66.6%  _+  6.3% 
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periments involving fibroblasts obtained from 6 d in vivo 
degenerating nerves, activity averaged 101% ___ 2% (SEM) 
of the activity of rGM-CSF (7.4 pg/ml). Inhibition of activ- 
ity by the activity blocking GM-CSF mAb was tested in 
one experiment and reached 55 %. The production of GM- 
CSF activity by fibroblasts was further verified using the 
mixed GM colony formation assay. Monolayers of fibro- 
blasts  originating from 6  d  in  vivo degenerating nerves 
were overlaid by bone marrow cells in soft agar.  Mixed 
GM colonies were detected 7-10 d there after, indicating 
the presence of GM-CSF activity. The GM-CSF molecule 
was further detected by ELISA in CM of nerve derived fi- 
broblasts that were grown in regular medium or medium 
supplemented by rlL-11~ and rTNFot (see below), and me- 
dium supplemented by 1 ~g/ml LPS (not shown). 
Nerve derived macrophages produced minute levels of 
GM-CSF. The MP differentiation assay was used to test 
CM of macrophages obtained from 5-7 d freeze-damaged 
nerves. In such preparations the normal nonneuronal cell 
population  that  had  been  destroyed by  freezing  is  re- 
placed, primarily, by recruited macrophages, and only to a 
lesser extent by fibroblasts (28). We were unable to detect 
GM-CSF  activity in  either one of three experiments in 
which  macrophage  CM  were tested  (Fig.  4  B).  Freeze- 
damaged nerve derived macrophages were allowed to pro- 
duce CM for 24 h  in medium supplemented by 1 ~g/ml 
LPS,  which  amplifies  GM-CSF  production (see  below). 
CM were assayed by ELISA and GM-CSF levels detected 
were 0.25 pg/5 ×  105 cells __. 0.11 (SEM; six experiments). 
In comparison, thioglycolate elicited peritoneal macrophages 
that  were  exposed to  LPS  as  above produced 25.30 pg 
GM-CSF/5  ×  105 cells _+ 0.33 (SEM, three experiments). 
The failure of nerve derived macrophages to produce sig- 
nificant levels of GM-CSF was also deduced from six ex- 
periments in which we could not detect GM-CSF in media 
conditioned for 24 h by 6 d freeze-damaged nerve prepara- 
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Figure 6.  IL-I~ and TNFet induce an increase in GM-CSF pro- 
duction by nerve explants (A) and nerve-derived cultured fibro- 
blasts (B). (,4) Nerve explants were incubated in medium (Ex) and 
medium supplemented  by 100 U/ml of rlL-11$ (ILl) or 40 ng/ml 
of rTNFet (TNIO  for 48 h. (B) Nerve derived fibroblasts were in- 
cubated in medium (Fib) and medium supplemented by 100 U/ml 
of rIL-1l~ (ILl) or 100 ng/ml of rTNFet (TNF) for 48 h. CM were 
assayed for GM-CSF production by ELISA. The results are ex- 
pressed  as percent of production by nerve explants  and fibro- 
blasts incubated in regular medium. Bars represent averages, er- 
ror bars +_ 1 SEM, n = number of experiments. 
tions neither by ELISA nor by the MP cell differentiation 
assay.  Determined  by  ELISA,  freeze-damaged  nerve 
preparation exposed to 50 p~g/ml LPS for 24 h  in culture 
produced 0.92  +-- 0.05 pg GM-CSF/mg wet weight tissue 
(SEM; three experiments). To test for the effectiveness of 
LPS, we  exposed 6  d  Wallerian  degenerating nerves to 
LPS, as above, and detected production levels of 62.18 +__ 
7.65 pg GM-CSF/mg wet weight tissue in 24 h  (SEM, six 
experiments). GM-CSF production by Wallerian degener- 
ating nerves is amplified by LPS (compare to Fig. 3). 
Schwann cells did not produce GM-CSF. The MP differ- 
entiation assay was used to test CM of Schwama cells ob- 
tained from 5-7 d  in vivo degenerating nerves. We were 
unable to detect GM-CSF activity in either one of four ex- 
periments in which Schwann cells CM were tested (Fig. 4 
B). The failure of cultured Schwann cells to produce GM- 
CSF activity was further verified in three mixed GM col- 
ony formation assays that gave negative results. We were 
further unable  to detect GM-CSF by ELISA in  CM  of 
Schwann cells that were either or not exposed to 1 ~g/ml 
LPS for 24 h. 
GM-CSF Production Is Up-regulated 
by IL-l[3 and TNFa 
IL-113 and TNFot are the first cytokines to be produced in 
response to tissue damage and, in turn, they initiate a cas- 
cade of inflammatory and immune related events (8, 9), 
one of which is the induction of GM-CSF production in 
macrophages, fibroblasts and endothelial cells (3, 5, 11, 16, 
17, 33, 38). We tested, therefore, whether IL-113 and TNFa 
can increase GM-CSF production in lesioned nerves and 
nerve derived fibroblasts as well. Intact nerve explants and 
nerve derived fibroblasts were exposed to rIL-1[3 and rT- 
NFct for 48 h  and  CM assayed for GM-CSF content by 
ELISA.  rIL-113 and  rTNFa  significantly increased  GM- 
CSF production by nonneuronal cells in nerve explants, 
and by nerve derived fibroblasts in culture (Fig. 6). 
GM-CSF Up-regulates MAC-2 Expression in Schwann 
Cells, Macrophages, and Peripheral Nerve Tissue 
Nerve injury is followed by a dramatic increase in MAC-2 
expression by Schwann cells that normally do not display 
the molecule at all (28). GM-CSF can induce the up-regu- 
lation of surface expression of MAC-2 in Schwann cells. 
Schwann cells dissociated from intact nerves were seeded 
on laminin coated 96-well plates. Adherent Schwann cells 
were exposed to rGM-CSF for 4 d. A maximal increase in 
surface MAC-2 expression was obtained at a  concentra- 
tion of 66 pg/ml of the cytokine, reflecting a  2.7-fold in- 
crease  over  levels  of expression  by  Schwann  cells  that 
were cultured in regular medium (Fig. 7 B). No increase in 
surface  levels  of  MAC-2  were  obtained  when  cultures 
were exposed to 600 pg/ml of GM-CSF. GM-CSF thus has 
a dual effect on Schwann cell surface MAC-2 expression. 
It should be noted that levels of MAC-2 expressed by cul- 
tured Schwann cells that were not exposed to GM-CSF do 
not reflect levels of MAC-2 expression by Schwann cells 
residing  in  intact  nerves,  which  is  undetectable  (28). 
MAC-2 expression by these cultured cells is, most proba- 
bly, the result of them being in the presence of the GM- 
CSF  producing fibroblasts  (see  above) for at  least  3  d, 
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from fibroblasts during the course of cell dissociation. 
The vast majority of macrophages that reside  in  Wal- 
lerian degenerating nerves express MAC-2.  Macrophage 
cell  cultures  were  established  from nerve segments  that 
were  allowed  to  degenerate  in  vivo for 5  d.  Cells  were 
stained immunohistochemically to visualize surface associ- 
ated MAC-2.  Of 1350  cells that were randomly sampled, 
98% displayed MAC-2 on their surface. In contrast, only 
60-70%  of blood monocytes, the pool from which tissue 
macrophages  are  drawn  from,  display  surface  MAC-2 
(24). Since recruited macrophages become activated, they 
are  expected to up-regulate MAC-2  expression  (10).  To 
test whether GM-CSF could have been involved in the up- 
regulation of surface expression of MAC-2 in tissue mac- 
rophages,  we  examined  peritoneal  macrophages  before 
and  after  exposure  to  rGM-CSF.  We  chose  peritoneal 
macrophages because  they  arise  from the  same pool  of 
blood monocytes as do nerve macrophages, they display 
low levels of MAC-2 on their surface, and are easy to ob- 
tain. Resident peritoneal macrophages (obtained by peri- 
toneal  lavage)  were  seeded  in  96-well  plates  (15  x  ~04 
cells/well) and allowed to adhere to the dish for 2-4 h. Non 
adherent  cells  were  washed,  and  adherent  macrophages 
exposed to rGM-CSF for 4 d. Cell surface levels of MAC-2 
were determined by ELISA. Three and fivefold increases 
in surface levels of MAC-2 expression were obtained at a 
concentration of 66 pg/ml and 600 pg/ml of the cytokine, 
respectively (Fig. 7 A). 
We further tested the ability of rGM-CSF to up-regulate 
MAC-2 production in the peripheral nerve tissue. We first 
determined,  by ELISA,  the  time  course for the  "inher- 
ited" lesion induced increase in MAC-2 expression during 
in  vivo and  in  vitro degeneration.  In  vivo degenerating 
nerves were examined in three experiments. MAC-2 con- 
tents (percentages of MAC-2 content in 5 d  degenerating 
nerves ___ 1 standard error), were 1.6 ___ 0.2 in intact nerves, 
and 4.2 _+ 0.4 in 1 d, 12.9  _+ 1.6 in 2 d, and 70.6 __+ 6.5 in 3 d 
in vivo degenerating nerves. In vitro degenerating nerves 
were assayed at 6 h  time intervals. MAC-2 contents (per- 
centages of MAC-2 content in 6 d degenerating nerves ±  1 
standard error), were 1.5 --- 0.42 in intact nerves, and 1.3 --+ 
0.25 in 6 h, 2.2 __+ 0.25 in 12 h, 2.4 ___ 0.08 in 18 h, and 4.5 _ 
0.85 in 24 h degenerating nerves. Thus, the initial small but 
significant increase in MAC-2  content in in vitro degener- 
ating nerves occurred after 12 h of degeneration. Note that 
the initial increase in GM-CSF production occurred within 
the first 5  h  after lesion and thus precedes the initial in- 
crease in MAC-2 production that occurs 12 h after injury. 
We have used the time window of the first 2 d after injury 
to test for the additional effect of rGM-CSF on the "inher- 
ited" increase in MAC-2 content during in vitro degenera- 
tion. Intact nerve explants that were exposed for 48 h after 
explantation to 10 ng/ml rGM-CSF expressed significantly 
higher levels (1.7-fold increase)of MAC-2 than nerve ex- 
plants that were not exposed to rGM-CSF (Fig. 7 C). 
Discussion 
In the present study we provide evidence for a novel cas- 
cade  of  molecular  events  and  cellular  interactions  that 
take place during the course of Wallerian degeneration of 
mice peripheral nerves. Nerve injury induces non neuronal 
cells, primarily fibroblasts, to produce GM-CSF. GM-CSF, 
in turn, induces macrophages and Schwann cells to up-reg- 
ulate  surface  expression  of MAC-2.  The  injury  induced 
production  of GM-CSF is  mediated,  at  least  in  part,  by 
IL-1. We further suggest that the up-regulation of MAC-2 
expression is significant to myelin removal and, in turn, to 
regeneration for either one or two reasons. One, MAC-2 
may be directly involved in mediating myelin phagocyto- 
sis.  Second,  MAC-2  marks  activated  phagocytic macro- 
phages  regardless  of the  type  of phagocytic mechanism 
they use. 
GM-CSF  Production 
It is most probable that nonneuronal cells that reside in in- 
tact nerves do not  produce  GM-CSF. This conclusion is 
based on two observations. One, the lack of detection of 
the  GM-CSF mRNA in  intact  nerves.  Second,  the  GM- 
CSF  molecule  was  not  detected  by  two  site  sandwich 
ELISA in  CM produced by intact nerve explants during 
the first 3 h  after removal from animals. In contrast, non- 
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Figure  7.  GM-CSF  up-regu- 
lates  MAC-2  expression  by 
isolated  peritoneal  macro- 
phages, isolated Schwann cells, 
and Schwann  cells residing  in 
nerve explants.  (A) Peritoneal 
macrophages exposed to rGM- 
CSF (pg/ml as indicated) for 4 d 
express  significantly  higher 
levels  of surface  MAC-2  than 
macrophages cultured in regu- 
lar medium (P  <  0.008).  (B) 
Schwann  cells  derived  from 
nerve explants were exposed to rGM-CSF (pg/ml as indicated)  for 4 d. rGM-CSF has a dual effect on cultured Schwann cells. At a con- 
centration of 66.6 pg/ml, Schwann ceils express significantly higher levels of surface MAC-2 than cells cultured in regular medium (P < 
0.028). At a concentration of 600 pg/ml surface levels of MAC-2 do not differ from those in cells cultured in regular medium. (C) Intact 
nerve explants exposed to rGM-CSF (ng/ml as indicated)  for 48 h express significantly higher levels of MAC-2 than explants cultured in 
regular medium (P < 0.014). Bars represent averages, error bars -1 SEM, n = number of experiments.  Two-tailed levels of significance 
by the Mann Whitney U test. In C, four nerves were examined in each one of the experiments that were done in quadruplicates. 
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ing nerves produce GM-CSF. This conclusion is based on 
four  independent  lines  of  observations.  First,  GM-CSF 
mRNA was detected in in vitro degenerating and in vivo 
degenerating nerves. Second, the identification and detec- 
tion  of  the  GM-CSF  molecule  by  two  site  sandwich 
ELISA in CM of in vitro and in vivo degenerating nerves. 
Third, the detection of GM-CSF bioactivity in CM by the 
mixed granulocye-macrophage colony formation and the 
MP  cell differentiation assays.  Fourth,  the  inhibition  of 
GM-CSF bioactivity in CM by GM-CSF activity blocking 
monoclonal antibodies. 
In  vivo,  the  up-regulation  of GM-CSF  production  is 
rapid  and continuous. It was detected as early as of the 
fourth h  after nerve injury, and continued for the entire 
2 wk after lesion period tested. The in vitro production is 
phasic.  It subsided to very low levels 1-2 d  after injury. 
Levels of GM-CSF  production by in  vivo degenerating 
nerves were further augmented by the exposure to LPS, 
thus  suggesting  that  infection  and  other  inflammatory 
stimuli can amplify GM-CSF production already induced 
by trauma. 
The nonneuronal cells that compose intact and in vitro 
degenerating nerves  are  primarily  Schwann  ceils,  fibro- 
blasts, and endothelial cells. Macrophages that are scarce, 
become numerous during in vivo Wallerian degeneration, 
following their recruitment from the circulation (28,  31, 
35).  Fibroblasts  can account for GM-CSF production in 
the in vitro and in vivo degenerating nerves. This conclu- 
sion is based on the detection of GM-CSF production by 
the nerve derived fibroblasts (by ELISA, MP differentia- 
tion assay, and GM colony forming assay). Our results are 
in  accord  with  previous  observations  demonstrating 
GM-CSF production by fibroblasts that reside in other tis- 
sues (16, 38). We could not detect GM-CSF in CM of cul- 
tured Schwann cells. We could detect very little GM-CSF 
production, if any, by macrophages that were present in or 
dissociated from freeze-damaged nerves, ff the conduct of 
dissociated Schwann cells and macrophages in vitro is a re- 
flection of their behavior in vivo, then neither cell type 
adds significantly to the production of GM-CSF during the 
course of in vivo Wallerian degeneration. Of particular in- 
terest is the finding of the poor production of GM-CSF by 
nerve derived macrophages, since activated macrophages 
that reside in other tissues (peritoneal, for example, in the 
present study) produce high levels of GM-CSF. Vascular 
endothelial  cells  can  also  produce  GM-CSF  (3,  5,  33). 
Since these cells are present in peripheral nerves, the pos- 
sibility that they may have contributed to the production 
of GM-CSF in degenerating nerves remains unresolved. 
It is very likely that IL-1 mediates the up-regulation of 
GM-CSF production during the course of Wallerian de- 
generation. This suggestion is supported by three observa- 
tions. One, that ILl-J3 and TNFet are the first cytokines to 
be produced in response to tissue damage (8, 9). Second, 
our present observation that rlL-1[~ increased the produc- 
tion of GM-CSF in nerve explants and nerve derived fi- 
broblasts. Third, our detection of IL-1 activity production 
in 5 h in vitro and 5-7 d in vivo degenerating mice nerves 
(29). We presently demonstrate that TNFot can also up- 
regulate GM-CSF production. We have little evidence that 
TNFet does so during the course of Wallerian degenera- 
tion since we barely were able to detect TNFot, by ELISA 
at a sensitivity of 10 pg/ml, in some of the same samples of 
CM in which we were able to detect GM-CSF (unreported 
results). 
GM-CSF Up-regulates Schwann and Macrophage 
Cell Surface Expression of  MA  C-2 
GM-CSF that is produced during in-vivo Wallerian degen- 
eration up-regulates cell surface expression of MAC-2 by 
Schwann cells that normally do not express MAC-2 (28). 
Three lines of observation support this conclusion. One, 
rGM-CSF increased cell surface expression of MAC-2 by 
cultured Schwann cells. Second, GM-CSF activity produc- 
tion preceded the increase in MAC-2  expression during 
the course of both in vitro and in vivo degeneration by sev- 
eral hours. Third, the addition of rGM-CSF to nerve ex- 
plants during their first 48 h in culture added significantly 
to the "inherited" lesion induced increase in MAC-2 ex- 
pression by Schwann cells. 
GM-CSF that is produced during in-vivo Wallerian de- 
generation up-regulates cell surface expression of MAC-2 
by recruited macrophages. This suggestion is based on the 
following observations. ~We presently show that  98%  of 
macrophages that reside in Wallerian degenerating nerves 
express  MAC-2,  whereas  only 60-70%  of blood  mono- 
cytes, the source of macrophage recruitment, do so (23, 
24). We further demonstrate that cell surface expression of 
MAC-2 is up-regulated by GM-CSF in non activated peri- 
toneal macrophages that originate from blood monocytes 
as do macrophages that reside in Wallerian degenerating 
nerves.  Our  observations  and  suggestions  are  in  agree- 
ment with previous findings. One, that the percentage of 
macrophage that display cell surface MAC-2 and levels of 
MAC-2 expressed by individual cells are subject to modu- 
lation by changing environmental conditions (12, 23, 24). 
Second,  that  GM-CSF  activates  macrophages  and  con- 
comitantly up-regulates MAC-2 expression (10). 
It is most likely that the concentrations of GM-CSF that 
we have used to test for its effect on macrophages and 
Schwann  are  within  physiological range.  Taking  a  GM- 
CSF production rate of 10 pg/mg/5h, for example (Fig. 2), 
and assuming a volume of I  ixl for 1 mg tissue weight, the 
above production rate will build up a concentration of 10 
ng/ml. This is  a  rough estimate which is  not taking into 
consideration that the extracellular volume of the tissue is 
much  smaller,  thus  suggesting  that  the  concentration of 
the cytokine may reach much higher levels. We have dem- 
onstrated that GM-CSF modulates macrophage precursor 
cell survival and surface MAC-2 expression in the concen- 
tration range of 1 pg/ml to  1,000  pg/ml  (Fig.  2), macro- 
phage and Schwann surface expression of MAC-2 in the 
concentration range of 60-600 pg/ml (Fig. 7), and MAC-2 
content in an in vitro degenerating nerve at a concentra- 
tion of 10 ng/ml (the effective concentration is likely to be 
lower because of diffusion barriers for a protein into a tis- 
sue). 
Conclusion 
Our data suggest the following sequence of events to take 
place during the course of Wallerian degeneration. Nerve 
lesion is followed by GM-CSF production which is medi- 
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source for GM-CSF  production,  GM-CSF  activates  mac- 
rophages  and  concomitantly  induces  the  expression  of 
the  galactose  specific  lectin  MAC-2  on  the  surfaces  of 
macrophages  and Schwann. MAC-2  thus marks activated 
phagocytic macrophages,  and as a cell surface associated 
molecule may also be instrumental in lectin-mediated phago- 
cytosis of myelin. 
In the present study we have focused on GM-CSF  as a 
macrophage  activator  and an up-regulator of MAC-2  ex- 
pression. GM-CSF could play additional roles in Wallerian 
degeneration. In support of this notion, GM-CSF levels re- 
main  high  after  phagocytosis  is  complete.  Examples  of 
such additional roles could include the modulation of IL-1 
activity present in injured nerves  (29)  by increasing  IL-1 
receptor antagonist production (15), and thus affect, indi- 
rectly, nerve growth factor synthesis (19).  GM-CSF could 
also affect the endothelial cell wall of capillaries that sup- 
ply blood to peripheral nerves by inducing endothelial cell 
proliferation and migration (6, 14). 
Our present findings further indicate that fibroblasts, by 
producing  GM-CSF  and  thereby  affecting  Schwann  cell 
and macrophage function, play a significant role in the cas- 
cade  of  molecular  events  and  cellular  interactions  that 
characterize  WaUerian  degeneration.  This  notion, is  fur- 
ther supported by previous findings of ours that nerve res- 
ident fibroblasts produce apolipoprotein E  (30) and inter- 
leukin-6 (27). 
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